TY  - GEN
AU  - Fox,Elizabeth
AU  - Maris,John M
AU  - Widemann,Brigitte C
AU  - Meek,Kysa
AU  - Goodwin,Anne
AU  - Goodspeed,Wendy
AU  - Kromplewski,Marie
AU  - Fouts,Molly E
AU  - Medina,Diane
AU  - Cho,Steve Y
AU  - Cohn,Susan L
AU  - Krivoshik,Andrew
AU  - Hagey,Anne E
AU  - Adamson,Peter C
AU  - Balis,Frank M
TI  - A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
SN  - 1078-0432
PY  - 2006///1204
KW  - Administration, Oral
KW  - Adolescent
KW  - Child
KW  - Child, Preschool
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Male
KW  - Neoplasm Recurrence, Local
KW  - drug therapy
KW  - Neoplasms
KW  - Sulfonamides
KW  - administration & dosage
KW  - Tubulin Modulators
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-06-0534
ER  -